QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:PULM

Pulmatrix (PULM) Stock Price, News & Analysis

$1.75
+0.13 (+8.02%)
(As of 03:13 PM ET)
Today's Range
$1.56
$1.85
50-Day Range
$1.62
$2.01
52-Week Range
$1.55
$3.15
Volume
38,150 shs
Average Volume
17,327 shs
Market Capitalization
$6.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Pulmatrix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
505.5% Upside
$10.00 Price Target
Short Interest
Healthy
0.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Pulmatrix in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.79 out of 5 stars

PULM stock logo

About Pulmatrix Stock (NASDAQ:PULM)

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

PULM Stock Price History

PULM Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com
Cipla Ltd CIPLA
Pulmatrix shuts down study, explores sale
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Pulmatrix Inc PULM
Pulmatrix Down on Q3 Results
Aspergillosis Treatment Research Report 2023
See More Headlines
Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/29/2022
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PULM
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+498.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,840,000.00
Net Margins
-238.89%
Pretax Margin
-238.89%

Debt

Sales & Book Value

Annual Sales
$6.07 million
Book Value
$8.55 per share

Miscellaneous

Free Float
3,520,000
Market Cap
$6.10 million
Optionable
Not Optionable
Beta
0.95
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Teofilo David Raad MBA (Age 54)
    President, CEO & Director
    Comp: $772.7k
  • Mr. Peter Ludlum CMA (Age 69)
    MBA, Interim CFO and Principal Accounting & Financial Officer
    Comp: $398.58k
  • Dr. Margaret M. Wasilewski M.D. (Age 67)
    Chief Medical Officer
    Comp: $585.84k
  • Dr. Alexander M. Klibanov Ph.D. (Age 74)
    Founder

PULM Stock Analysis - Frequently Asked Questions

Should I buy or sell Pulmatrix stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PULM shares.
View PULM analyst ratings
or view top-rated stocks.

What is Pulmatrix's stock price target for 2024?

1 equities research analysts have issued 12 month target prices for Pulmatrix's shares. Their PULM share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 505.5% from the stock's current price.
View analysts price targets for PULM
or view top-rated stocks among Wall Street analysts.

How have PULM shares performed in 2024?

Pulmatrix's stock was trading at $1.86 on January 1st, 2024. Since then, PULM shares have decreased by 11.2% and is now trading at $1.6516.
View the best growth stocks for 2024 here
.

Are investors shorting Pulmatrix?

Pulmatrix saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 400 shares, a decrease of 97.4% from the February 29th total of 15,300 shares. Based on an average daily volume of 17,900 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company's stock are sold short.
View Pulmatrix's Short Interest
.

When is Pulmatrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our PULM earnings forecast
.

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) issued its quarterly earnings data on Tuesday, March, 29th. The biotechnology company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($1.60) by $0.83. Pulmatrix had a negative trailing twelve-month return on equity of 64.09% and a negative net margin of 238.89%.

When did Pulmatrix's stock split?

Shares of Pulmatrix reverse split on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.96%), Vanguard Group Inc. (0.96%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Pulmatrix?

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PULM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners